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Abstract
Purpose
The purpose of this study is to assess the incremental effect of tissue plasminogen activator
(t-PA) dose on pulmonary artery pressure (PAP) and bleeding during catheter directed
thrombolysis (CDT) of submassive pulmonary embolism (PE).
Materials and methods
Records of 46 consecutive patients (25 men, 21 women, mean age 55±14 y) who underwent
CDT for submassive PE between September 2009 and February 2017 were retrospectively
reviewed. Mean t-PA rate was 0.7±0.3 mg/h. PAP was measured at baseline and daily until
CDT termination. Mixed-effects regression modeling was performed of repeated PAP mea-
sures in individual patients. Bleeding events were classified by Global Utilization of Strepto-
kinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) and t-
PA dose at onset.
Results
Mean t-PA dose was 43.0±30.0 mg over 61.9± 28.8 h. Mean systolic PAP decreased from
51.7±15.5 mmHg at baseline to 35.6±12.7 mmHg at CDT termination (p<0.001). Mixed-
effects regression revealed a linear decrease in systolic PAP over time (β = -0.37 (SE =
0.05), p<0.001) with reduction in mean systolic PAP to 44.8±1.9 mmHg at 12 mg t-PA/20 h,
39.5±2.0 mmHg at 24 mg t-PA/40 h, and 34.9±2.1 mmHg at 36 mg/60 h. No severe, one
moderate, and 8 mild bleeding events occurred; bleeding onset was more frequent at�24
mg t-PA (p <0.001). One patient expired from cardiopulmonary arrest after 16 h of CDT
(15.4 mg t-PA); no additional intra-procedural fatalities occurred.
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Conclusion
Increased total t-PA dose and CDT duration were associated with greater PAP reduction
without increased bleeding events.
Introduction
Prospective trials investigating catheter directed thrombolysis (CDT) of submassive pulmonary
embolism (PE) demonstrated reduction of pulmonary artery pressure (PAP) [1] and right heart
strain [2, 3] in CDT treatment arms. These results are corroborated by findings from the prospec-
tive multicenter Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter
Thrombolysis (PERFECT) registry [4] and retrospective studies [5–12]. However, thrombolytic
dose and duration were limited to 4–24 mg tissue-plasminogen activator (t-PA) over 2–24 h in the
prospective trials [1–3]; patients in PERFECT received a mean t-PA dose of 28±11 mg over 23.2
±8.1 h using ultrasound assisted thrombolysis (USAT) or 20.8±11.5 h with standard CDT [4]. The
ULTIMA study [2] reported a 10% minor bleeding complication rate and no major bleeding; the
SEATTLE II study [1, 13] reported a 20%, 10.7% and 0.7% incidence of mild, moderate and severe
bleeding events respectively. In the OPTALYSE PE study, four patients (4%) suffered 5 major
bleeding events, included one intracranial hemorrhage attributed to CDT; this patient had been
randomized to receive 12–24 mg t-PA over 6 h, a higher dose over a shorter duration compared to
the ULTIMA (10–20 mg t-PA over 15 h) and SEATTLE II (24 mg t-PA over 12–24 h) trials [3].
The highest rates of major bleeding in these trials have occurred with t-PA dosage of�2 mg/h,
raising the possibility that administration rates above 1 mg/h may decrease safety of CDT [14].
While these studies indicate that CDT reduces pulmonary hypertension and right heart
strain in patients with submassive PE, the incremental impact of increased cumulative throm-
bolytic dose on PAP and hemorrhagic complications, particularly with cumulative t-PA doses
above 24 mg, has not been established. We have therefore investigated the hypothesis that
CDT with a low dose rate (�1 mg/h) extended beyond published trial protocols further
reduces PAP without an increase in bleeding complications.
Materials and methods
This single-center retrospective cohort study was compliant with the Health Insurance Porta-
bility and Accountability Act. Institutional Review Board approval was obtained with waiver
of informed consent for review of records.
Study population
Medical records and imaging studies were reviewed for 46 consecutive patients (25 men, 21
women) who underwent CDT for submassive PE between September 2009 and February 2017
at a tertiary care hospital. Submassive PE was defined by 2011 American Heart Association
(AHA) guidelines [15]. PE was confirmed with computed tomography angiography (CTA,
n = 44), lung perfusion single photon emission computed tomography-computed tomography
(SPECT-CT, n = 1), and digital subtraction angiography (DSA, n = 1). This study includes 17
patients who were previously published [16] in order to provide new information regarding
changes in PAP in serial measurements during CDT. Upon review of data, the prior study
included 2 patients who met AHA criteria for massive pulmonary embolism, including one
patient who developed intracranial hemorrhage during thrombolysis; these patients were
therefore excluded from this analysis.
Catheter-directed thrombolysis of submassive pulmonary embolism
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Baseline patient characteristics
Mean patient age was 55±14 years; 31 (67%) patients were African American, 6 (13%) Cauca-
sian, and 6 (13%) Hispanic or Latino (Table 1). Mean time from symptom onset to PE diagno-
sis and initiation of CDT was 2.6±2.9 d and 3.4±3.2 d respectively. The most common
presenting symptoms were dyspnea (n = 42, 91%), chest pain (n = 24, 52%), and syncope
(n = 11, 24%). CT findings of right ventricle (RV) strain were present in 43 of 44 (98%)
patients with a mean RV/left ventricle (LV) diameter ratio of 1.6±0.7. Echocardiographic evi-
dence of right heart strain [15] was observed in 35 of 42 (83%) patients. Twenty-seven (59%)
patients had an elevated simplified pulmonary embolism severity index (sPESI) score [17].
Three patients had a contraindication to systemic lysis (C3-C7 laminectomy 20 d prior, n = 1;
gastric band placement 7 d prior, n = 1; uterine myomectomy 8 d prior, n = 1). CDT was the
only thrombolytic therapy performed for all patients.
CDT technique
The right (n = 41) or left (n = 2) common femoral vein, or right internal jugular vein (n = 2),
was accessed with a 21-gauge needle (Micropuncture Introducer Set; Cook Medical, Bloom-
ington, Indiana) under real-time sonographic guidance. Vascular access was dilated to accept
a 5-French (n = 1), 7-French (n = 30), or 8-French (n = 15) vascular sheath (Pinnacle; Terumo,
Somerset, New Jersey). A 7-French (APC, Cook Medical, Bloomington Indiana; n = 43) or
5-French (SOS Omni Flush, Angiodynamics, Latham New York; n = 1; APC, Cook Medical,
Bloomington Indiana; n = 1) was positioned in the main PA and baseline PAP determined.
Angiography was performed with iohexol (Omnipaque 300; GE Healthcare, Little Chalfont,
United Kingdom). CDT was performed with a single catheter in the right or left PA (n = 45)
or bilateral PA catheters (n = 1). When a single catheter was used, it was repositioned into the
contralateral PA at operator discretion in 17 patients. Tissue plasminogen activator (t-PA,
Activase; Genentech, San Francisco, California) was instilled through the PA catheter(s) at a
mean rate of 0.7±0.3 mg/h (range, 0.4–1.1 mg/h). The dose rate was per operator discretion
based upon clinical acuity and bleeding risk. Intravenous heparin was administered
Table 1. Patient demographic and clinical characteristics (n = 46).
GENDER FEMALE 21 (46%)
Male 25 (54%)
Mean Age (years) 55±14
Body mass index (kg/m2) 34.5±10.0
Ethnicity/race African American 31 (67%)
Caucasian 6 (13%)
Hispanic or Latino 6 (13%)
Middle Eastern 3 (7%)
Risk factors Obesity 29 (63%)
Hypertension 23 (50%)
Immobility within 30 d 11 (24%)
Previous venous thromboembolism 9 (20%)
Diabetes 7 (15%)
Recent surgery (within 30 d) 6 (13%)
Active malignancy 6 (13%)
Oral contraceptive use 3 (7%)
Hypercoagulable disorder 2 (4%)
End stage renal disease 2 (4%)
Family history of venous thromboembolism 1 (2%)
https://doi.org/10.1371/journal.pone.0211701.t001
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concurrently with goal partial thromboplastin time (PTT) of 60–80 s. Patients were monitored
in the intensive care unit (ICU) during CDT. Serial fibrinogen levels were measured every 6 h
(range 185–946 mg/dL). Angiography with PAP measurement was performed daily until CDT
termination. CDT was terminated at operator discretion based on symptomatic improvement,
reduction in PAP and clot burden. Hemostasis was achieved at the venotomy site with manual
compression upon termination. Mechanical clot disruption techniques were not utilized.
Measured outcomes
Serial systolic PAP measured during daily follow-up was tabulated. Duration of ICU and total
hospital stay were also recorded. Technical success was defined as successful PA catheter place-
ment and fibrinolytic agent delivery [18].
Procedural (during CDT) and postprocedural (within 30 d of CDT) adverse events were
categorized according to the Society of Interventional Radiology classification [19]. Bleeding
complications were additionally classified according to GUSTO [20] and by onset before or
after infusion of 24 mg t-PA [1, 2, 4, 11].
Patients were followed until death or the last documented clinical encounter. Post-CDT
right heart function was assessed with echocardiography in 26 (56%) patients at a mean 10.4
±1.9 months after CDT and with contrast enhanced CT in 13 (28%) patients at a mean 17.4
±18.8 months after CDT. Echocardiographic evidence of right heart strain was categorized as
normal, mild, moderate, or severe using guidelines from the American Society of Echocardiog-
raphy [21]. Imaging outcomes of patients with baseline and follow-up echocardiography were
stratified by total infusion of less than or greater than 24 mg t-PA.
Statistical analysis
Mixed-effects regression models were employed to examine changes in repeated measures of
PAP in individual patients by increasing cumulative t-PA dose over time. Random effects were
estimated to account for correlations between repeated measurements from the same individ-
ual. Likelihood ratio tests and fit statistics including Akaike information criterion (AIC) and
Bayesian information criterion (BIC) were used to select the best-fitted number of random
effects, as well as variance-covariance structure of repeated measurements. Dose values at each
time point were treated as time-varying covariates, and the interaction of dose with time was
tested to examine how dose values affect PAP over time. Model estimates and standard errors
were reported from the final model. Baseline vs. post CDT findings of right heart strain on
echocardiography, severity of right heart strain on echocardiography and severity of right
heart strain on CT were statistically compared using McNemar’s test, Wilcoxon Signed-Rank
test, and T-test respectively. Distributions of mean cumulative t-PA dose and systolic PAP for
patients who underwent echocardiography or CT follow-up were compared with the remain-
ing cohort using the Mann-Whitney U test. Incidence of bleeding event onset before or after
administration of 24 mg t-PA was compared using Fisher’s Exact Test. Analyses were per-
formed with SAS (version 9.4, SAS Institute Inc., Cary North Carolina).
Results
Procedural characteristics
All procedures were technically successful. CDT was performed for a mean 61.9±28.8 h with
mean cumulative t-PA dose of 43.0±30.0 mg. Intraprocedural angiography and PAP measure-
ment occurred at a mean 19.5±4.5 (n = 46), 43.0±4.9 (n = 40), 63.9±5.7 (n = 26), 89.2±3.7
(n = 13), 113.5±2.1 (n = 4) and 138.0 h (n = 1) after initiation of CDT with corresponding
Catheter-directed thrombolysis of submassive pulmonary embolism
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mean cumulative t-PA dose of 11.8±4.8, 27.6±10.4, 42.4±14.4, 64.0±23.8, 98.9±31.3 and 158.3
mg respectively. Measured mean systolic PAP at these intervals was 43.0±12.3, 41.6±13.6, 37.6
±14.5, 34.5±14.3, 48.0±17.3, and 39.0 mmHg. Mixed-effects regression revealed a linear
decrease in systolic PAP by increasing t-PA dose (Fig 1), with a 0.3 mmHg/h decrease in sys-
tolic PAP (β = -0.37 (SE = 0.05), p< 0.001), and no observed association between mean patient
dose and this trend (p = 0.37). Recorded and mixed-effects regression fitted systolic PAP by t-
PA dose and time are summarized in Table 2.
Fig 1. Systolic PAP as a function of cumulative t-PA dose for each patient (light lines). Mixed-effects regression
model (dense line) revealed a significant linear decrease in systolic PAP (β = -0.37 (SE = 0.05), p< 0.001).
https://doi.org/10.1371/journal.pone.0211701.g001
Table 2. Mean systolic pulmonary artery pressure and cumulative t-PA dose at follow-up intervals.
RECORDED� MIXED-EFFECTS REGRESSION MODEL VALUES�
Mean follow-up
interval (hours)
Mean cumulative
administered t-PA dose
(mg)
Mean systolic pulmonary
artery pressure (mmHg)±SD
Follow-up
interval (hours)
Cumulative administered
t-PA dose (mg)
Mean systolic pulmonary
artery pressure (mmHg)±SE
Baseline (n = 46) N/A 51.7±15.5 Baseline N/A 50.8±2.1
19.5±4.5 (n = 46) 11.8±4.8 43.0±12.3 20 12.0 44.8±1.9
43.0±4.9 (n = 40) 27.6±10.4 41.6±13.6 40 24.0 39.5±2.0
63.9±5.7 (n = 26) 42.4±14.4 37.6±14.5 60 36.0 34.9±2.1
�All p values < 0.001.
https://doi.org/10.1371/journal.pone.0211701.t002
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Evaluation of right heart function after CDT
Patients were followed for a mean 22.9±26.7 months. Both baseline and follow-up echocardio-
grams were performed in 18 (39%) patients at a mean follow-up of 10.4±19.6 months post
CDT. Among patients with both baseline and follow-up echocardiograms, right heart strain
was present in 4 of 18 (22%) patients on follow-up compared to 14 of 18 (78%) at baseline
(p = 0.002); severity of right heart strain also decreased between baseline and follow-up (Fig
2A, p<0.001). Fig 2B illustrates changes in severity of right heart strain on echocardiography
stratified by t-PA dose. Among patients with follow-up echocardiography, 8 of 9 (88.9%)
patients who received>24 mg t-PA had echocardiographic evidence of right heart strain at
baseline compared to 6 of 9 (66.7%) of patients who received<14 mg t-PA. On follow-up
echocardiography, 7 of 9 (77.8%) patients who received >24 mg t-PA had no evidence of right
heart strain, compared to 8 of 9 (88.9%) patients who received<24 mg t-PA. Patients with
both baseline and follow-up echocardiograms were administered a similar cumulative t-PA
dose (35.1±23.9 mg, p = 0.17) and had similar systolic PAP at baseline (49.5±12.8 mmHg,
p = 0.68) and CDT completion (35.1±14.8 mmHg, p = 0.55) compared to the remainder of the
cohort.
Fig 2. (A) Changes in severity of right heart strain on echocardiography from baseline to follow-up (p<0.001). (B) Changes in right heart strain on
echocardiography stratified by total t-PA dose. (C) Decrease in RV/LV diameter ratio on CT from baseline to follow-up (p<0.001).
https://doi.org/10.1371/journal.pone.0211701.g002
Catheter-directed thrombolysis of submassive pulmonary embolism
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Baseline and follow-up contrast enhanced CT was performed in 13 (28%) patients at a
mean 17.4±18.8 months post CDT and demonstrated a mean RV/LV diameter ratio decrease
from 1.6±0.7 to 1.0±0.2 (Fig 2B, p<0.001). Patients with CT follow-up received a similar dose
of t-PA (39.9±23.4 mg, p = 0.59) and had similar PAP at baseline (47.8±15.6 mmHg, p = 0.65)
and CDT completion (32.5±13.4 mmHg, p = 0.35) compared to patients without CT follow-
up.
Clinical outcomes and adverse events
Presenting symptoms resolved in 45 (98%) of patients with a mean time to resolution of 1.8
±0.9 d. Mean ICU stay was 4.9±3.1 d and mean total hospital stay was 8.0±5.4 d.
An intra-procedural complication occurred in 9 (19.6%) patients (Table 3). One (2%)
patient died 16 h after initiation of CDT (15.4 mg t-PA) from cardiopulmonary arrest attrib-
uted to PE (SIR grade 5). No additional moderate or severe intra-procedural adverse events
occurred. Mild intra-procedural bleeding (SIR grade 1, GUSTO grade 1) occurred in 8 patients
(18%) at a mean 38.4±20.4 h after initiation of CDT; mild bleeding complications included
small volume hemoptysis (n = 2), small hematoma or oozing at a venous access site (n = 5),
and transient gross hematuria after Foley catheter insertion during CDT (n = 1). No moderate
or severe intra-procedural bleeding events occurred.
Post-procedural complications were observed in 2 patients. A patient who underwent CDT
for 21.5 h (10.5 mg t-PA) developed retroperitoneal bleeding 24 hours after CDT termination,
requiring transfusion with 1 unit packed red blood cells (SIR grade 2, GUSTO grade 2), IVC
filter placement, and cessation of systemic anticoagulation for 10 d; the patient recovered and
the IVC filter was retrieved 136 d later. One patient died of sepsis 22 d after completion of
Table 3. Safety outcomes (n = 46).
MEAN ICU LENGTH OF STAY (D) 4.9±3.1
Mean total hospital length of stay (d) 8.0±5.4
All cause 30-day mortally, n (%) 2 (4%)
All procedural complications GUSTO mild, n = 8 (17%)
Occurrence at�24 mg t-PA infused, n (%) 7 (88%)�
Occurrence at >24 mg t-PA infused, n (%) 1 (12%)
SIR grade 5 (death), n = 1 (2%)
Occurrence at�24 mg t-PA, n (%) 1
(100%)
Occurrence at >24 mg t-PA, n (%) 0 (0%)
All post-procedural complications (within 30 d of
CDT)
GUSTO moderate, n = 1 (2%)
Cumulative t-PA dose administered �24 mg, n
(%)
1
(100%)
Cumulative t-PA dose administered >24 mg, n
(%)
0 (0%)
SIR grade 5 (death), n = 1 (2%)
Cumulative t-PA dose administered �24 mg, n
(%)
0 (0%)
Cumulative t-PA dose administered >24 mg, n
(%)
1
(100%)
Intensive care unit (ICU), catheter directed thrombolysis (CDT), Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries (GUSTO), Society of Interventional Radiology (SIR).
�p<0.001
https://doi.org/10.1371/journal.pone.0211701.t003
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CDT (SIR grade 5). No additional post-procedural deaths or bleeding events were observed
within 30 d of CDT.
Of the 9 total bleeding complications (1 moderate, 8 mild), 8 (89%) occurred at a cumula-
tive t-PA infusion dose of�24 mg (Table 3).
Discussion
Meta-analyses of prospective clinical trials evaluating systemic fibrinolysis for submassive PE
have suggested a decrease in all-cause mortality [22] or clinical deterioration [23, 24] com-
pared to anticoagulation alone, at the expense of an increased risk of major bleeding. Direct
instillation of a lower dose of fibrinolytic agent into the PA via CDT has been investigated with
the goal of achieving therapeutic benefit while minimizing bleeding complications. However,
the optimal dose, duration, and technique of CDT is not established. The higher rates of major
bleeding in the SEATTLE II study, in which the majority of patients received 2 mg t-PA/h, and
in the OPTALYSE PE trial arm receiving 12–24 mg/t-PA over 6 h, suggest that a dose rate of
over 1 mg t-PA/h may result in greater hemorrhagic complications [1, 3, 14]. The majority of
prospective and retrospective studies have assessed CDT with�24 mg t-PA; [1–5, 7–9, 11] the
impact of t-PA dose >24 mg, administered at a low (�1 mg/h) dose rate, upon PAP reduction
and bleeding risk is unclear.
In this study, a decrease in mean systolic PAP from 50.8±2.1 to 39.5±2.0 mmHg (11.3
mmHg reduction) was observed after CDT with 24 mg t-PA administered at a mean rate of 0.7
mg/h; this reduction is similar to the prospective ULTIMA (12.3 mm Hg reduction) [2] and
SEATTLE II (14.5 mm Hg reduction) [1] trials and initial results of the PERFECT registry
(14.0 mmHg reduction) [4]. However, the results of this study suggest that extending the dura-
tion of thrombolysis to administer >24 mg t-PA further decreases systolic PAP: additional
reductions of 4.6 mmHg and 6.4 mmHg were observed with increased cumulative t-PA dose
from 24 to 36 mg and 36 to 48 mg respectively (Fig 3). Extrapolation of the observed linear
decrease in systolic PAP for the higher t-PA doses administered to this cohort should be per-
formed with caution, as the number of patients who received, for example, >48 mg (n = 12),
or underwent CDT for>72 h (n = 13), may be inadequate to derive reliable conclusions.
Our findings raise the possibility that extending the duration of CDT to administer over 24
mg t-PA may further reduce prevalence of right heart strain in follow-up imaging. Although a
minority of patients in our study underwent echocardiography or CT follow-up, these patients
had similar distributions of cumulative t-PA dose and systolic PAP compared to patients with-
out imaging follow-up and appear representative of the entire cohort. In the ULTIMA [2] and
SEATTLE II [1] studies a 0.35±0.22 and 0.42±0.36 improvement in RV/LV diameter ratio was
observed, compared to 0.65±0.52 in this study; however, the greater mean improvement in
this study may be attributable to the long interval between CDT termination and echocardiog-
raphy (10.4 mo) and CT (17.4 mo). As illustrated in Fig 2B, among the subset of patients with
baseline and follow-up echocardiography (n = 18), patients who received >24 mg t-PA were
not more likely to have normal echocardiography on follow-up. However, a higher proportion
of these patients also had abnormal baseline echocardiograms compared to patients who
received<24 mg t-PA, and may have been selected for more prolonged CDT at operator dis-
cretion due to greater PE severity and lack of response to CDT at<24 mg t-PA. The impact of
extending CDT on improvement of right heart function would require confirmation in further
studies.
An increase in bleeding events was not observed with higher cumulative thrombolytic dose
and duration of CDT. A total of 8 (17%), 1 (2%), and 0 (0%) GUSTO-defined minor, moderate
and severe bleeding complications occurred; bleeding events were observed more commonly
Catheter-directed thrombolysis of submassive pulmonary embolism
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with�24 mg t-PA administered (Table 3). This statistical observation should be interpreted
with caution, as prior studies have demonstrated increased bleeding with more prolonged
thrombolysis [25]; in addition, two major hemorrhagic events, including one intracranial
hemorrhage, occurred in 18 patients assigned to the highest dose arm (12–24 mg t-PA over 6
h) in the OPTALYSE PE study[3]. However, the results of the presented cohort suggest that
prolongation of CDT with a low dose rate (<1 mg t-PA/h) beyond 24 mg t-PA to the average
dose of 43.0±30.0 mg administered in this study was well tolerated. We observed fewer moder-
ate and severe bleeding events than in the SEATTLE II study, and a similar low incidence of
clinically significant bleeding events compared to the PERFECT and ULTIMA studies
(Table 4).
Fig 3. Comparison of t-PA dose effect on systolic pulmonary artery pressure in prior CDT studies for submassive pulmonary embolism. � 28 mg t-PA or
2,67,101 International units of urokinase.
https://doi.org/10.1371/journal.pone.0211701.g003
Table 4. Comparison of bleeding complications to prior studies.
Study
Bleeding Complication Severity Current Study.1
(n = 46)
ULTIMA
(n = 30)
SEATTLE II1
(n = 150)
PERFECT2
(n = 101)
Mild, n (%) 8 (17.4%) 3 (10.0%)3 (20%) 13 (12.8%)
Moderate, n (%) 1 (2.2%) N/A 16 (10.7%) N/A
Major, n (%) 0 (0%) 0 (0%)4 1 (0.7%) 0 (0%)
1Bleeding complication categorized by Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO)
2Bleeding complications categorized by Society of Interventional Radiology Practice Guidelines
3Clinically overt bleeding not fulfilling criteria of major bleeding
4Bleeding associated with a fall in hemoglobin �2.0 g/dL or with transfusion of�2 units of red blood cells or involvement of a critical site (intracranial, intraspinal,
intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome).
https://doi.org/10.1371/journal.pone.0211701.t004
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Although extending thrombolysis to an average 43.0±30.0 mg t-PA was associated with an
additional decrease in PAP compared to 24 mg in this cohort, the benefit of further PAP
reduction on clinical outcomes such as exercise tolerance was not assessed and remains unes-
tablished. Any clinical benefit of extended CDT must be balanced with potentially increased
resource utilization in the form of prolongation of ICU length of stay during CDT. Although
increased CDT duration likely lengthened ICU stay (mean 4.9±3.1 d), the average hospital stay
(8.0±5.4 d) was similar to 8.9±3.4 d in ULTIMA [2], 8.8±5 d in SEATTLE II [1], and 8.2±4.8 d
in PERFECT [4].
Comparisons of results in this study of CDT are made to prior studies using USAT [1–4].
Based upon current knowledge, the comparison is valid, as a benefit of USAT over CDT has
not been demonstrated. Retrospective studies by Liang et al. and Graif et al. reported no differ-
ence in hemodynamic outcomes or procedural complication rates between USAT and stan-
dard CDT using conventional straight or pigtail-shaped multi-sidehole catheters [12, 26].
Within the PERFECT registry, no difference was observed in hemodynamic outcomes
between USAT and CDT groups [4]. Similarly, the prospective, randomized BERNUTIFUL
trial also showed no benefit to USAT compared to CDT for iliofemoral DVT [27]. Additional
technical differences in the presented cohort study may have impacted rates of PA pressure
reduction aside from t-PA dose. The majority of patients (97.8%) underwent CDT with a sin-
gle pigtail catheter positioned ipsilateral to the greatest clot burden. In contrast, bilateral
USAT catheters were utilized in 86% of patients in SEATTLE II and 87% in ULTIMA [1, 2].
Similar PA pressure reductions by t-PA dose were observed in this study compared to other
studies (Fig 3). To our knowledge, no direct comparison of unilateral versus bilateral catheters
has been performed to demonstrate the superiority of either approach, but it is conceivable
that that bilateral PA catheters may result in differences in PA pressure reduction or bleeding
complications compared to unilateral catheter placement. Finally, the rate of t-PA instillation
in this study (mean 0.7 mg/h) is lower compared to 1.3 mg/h for 87% of patients in ULTIMA,
2 mg/h for 86% of patients in SEATTLE II, and up to 4 mg/h in OPTALYSE PE [1–3]. While
higher dose rates may hasten hemodynamic improvement, the results of SEATTLE II and the
highest dose-rate arm of OPTALYSE PE raise the possibility that higher infusion rates are also
associated with more bleeding events [14].
The results of this study should be interpreted in the context of its non-randomized, retro-
spective study design. Without a control arm, it is unclear to what degree the incremental PAP
reduction was attributable to additional t-PA, or from anticoagulation and time. However, in
SEATTLE II [1] there was no discernible change in systolic PAP on echocardiography 48 h
after CDT completion when compared to systolic PAP at CDT completion. This study is also
limited by small sample sizes for t-PA doses above 48 mg t-PA (n = 12); therefore, mixed-
effects regression modeling for doses above 48 mg should be extrapolated with caution. Detec-
tion of adverse events was dependent upon medical records, and minor complications in par-
ticular may be underreported. As with other studies of CDT for PE, assessment and follow-up
for clinically important outcomes such as chronic thromboembolic pulmonary hypertension,
exercise tolerance, and quality of life was not performed. Evaluation of RV function after CDT
was not performed in a standardized fashion, and although the results of this study are promis-
ing, comparison of these results with prospective studies should be interpreted with caution.
This study included a high proportion of African American patients (67%) compared to other
studies (e.g. 14.7% in SEATTLE II, 3% in PERFECT, 36.6% in OPTALYSE PE) [1, 3, 4]; while
representation of African American patients begins to fill a major deficit in the literature,
patient demographics may theoretically affect external validity of this study. Finally, as with
other studies on CDT for submassive PE, t-PA dose was not adjusted for body weight; weight-
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based standardization of t-PA dose in CDT may provide more rigorous pharmacokinetic data
in future studies.
In conclusion, continuation of CDT beyond currently published trial protocols was associ-
ated with greater PAP reduction in patients with submassive PE without increased incidence
of bleeding events. Although the clinical impact of accelerated PAP reduction by prolongation
of CDT requires further investigation, an extended duration of thrombolysis administered at a
low dose rate (<1 mg/h t-PA) was well tolerated and should be considered for future clinical
trials assessing long-term outcomes of CDT for submassive PE.
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